cenacitinib

Cenacitinib is a **synthetic small molecule** and a **potent, selective allosteric inhibitor of tyrosine kinase 2 (TYK2)**, belonging to the Janus kinase (JAK) family[1][5][7][13]. It specifically targets the **pseudokinase (regulatory) domain** of TYK2, aiming for greater selectivity compared to ATP-competitive active site inhibitors[1][5]. Developed by **Ventyx Biosciences** as VTX958, cenacitinib is an oral drug candidate for **inflammatory and autoimmune conditions**, with the primary clinical focus on **Crohn’s disease**. It has also been evaluated for **psoriatic arthritis** and **psoriasis**, though current active trials are only in Crohn’s disease as of late 2024[4][6][7].

Other names

cenacitinib